Q-omics provides the consensus-scored PEX13 profile across patient tissues and cancer cell-line models. PEX13 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PEX13 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PEX13 RNA expression shows 20,804 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where PEX13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX13 survival associations across molecular data types. PEX13 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX13 RNA expression–survival associations across cancer types. High PEX13 expression shows unfavorable associations in ACC, LGG, PAAD, HNSC and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PEX13 RNA expression.
This table summarizes PEX13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PEX13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX13 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, LUAD and LUSC. The HNSC box plot shows higher PEX13 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with PEX13 in patient tissues and cancer cell lines. In patient samples, PEX13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
